A recent study published in the journal Lancet Gastroenterology and Hepatology has highlighted a serious issue: the drugs available to treat hepatitis B (HBV) are not being used enough, and starting treatment early could save many lives.
According to experts, more than 3,000 people die from hepatitis B every day. This means approximately two people every minute. For those who develop chronic HBV infection and do not receive treatment, there is a significant risk—between 20% to 40% may die without proper care.
Dr. John Tavis, a professor at Saint Louis University School of Medicine, emphasized that although current medications do not cure the virus, they are safe, effective, and affordable. Alarmingly, only less than 3% of individuals infected with HBV are currently receiving any treatment. “These medications are good drugs that are being badly underused,” Dr. Tavis stated.
The research shows that starting treatment early can slow down the disease’s progression and reduce liver damage over time. Chronic HBV can lead to liver cancer and liver failure over the course of 20 to 30 years. Furthermore, hepatitis B not only affects physical health but also brings emotional and social challenges, impacting overall quality of life.
One significant pathway of transmission is from an infected mother to her newborn. Often, these mothers are unaware they have the virus, leading to immense stress when they learn they may have unknowingly passed it on to their child.
Experts believe that increasing the use of these drugs could cut the incidence of liver cancer by 66% to 75%, saving millions of lives in the future.
The call to action is clear: increasing awareness and access to hepatitis B treatment is crucial for public health. By getting people on medication earlier, we can reduce both disease and death rates significantly.
-Rashmi Kumari




